UTHR Q1 2018 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$389M+5.0% YoY

Gross Profit

$336M86.3% margin

Operating Income

$307M78.9% margin

Net Income

$245M62.8% margin

EPS (Diluted)

$5.57

QoQ Revenue Growth

-16.2%

Cash Flow

Operating Cash Flow

$276M

Free Cash Flow

$238M

Stock-Based Comp.

-$101M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$632M

Stockholders' Equity

$2.4B

Cash & Equivalents

$933M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$389M	$371M	+5.0%
Gross Profit	$336M	$356M	-5.7%
Operating Income	$307M	$264M	+16.4%
Net Income	$245M	$179M	+36.9%

Revenue Segments

Remodulin

$127M33%

Adcirca

$98M25%

Tyvaso

$95M24%

Orenitram

$52M13%

Unituxin

$18M5%

Geographic Segments

U

$366M94%

European Union And Others

$23M6%